Ownership history in MORGAN STANLEY · 8 quarters on record
This page tracks every 13F SEC filing in which MORGAN STANLEY reported a position in NEUROSENSE THERAPEUTICS LTD (NRSN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 66,400 | -13,500 | -16.9% | 0.00% | $83K | $1.25 |
| 2025 Q2 | ADDED | 79,900 | +29,399 | +58.2% | 0.00% | $151K | $1.89 |
| 2025 Q1 | REDUCED | 50,501 | -52,080 | -50.8% | 0.00% | $47K | $0.93 |
| 2024 Q4 | ADDED | 102,581 | +101,081 | +6738.7% | 0.00% | $123K | $1.20 |
| 2024 Q2 | UNCHANGED | 1,500 | — | 0% | 0.00% | $2K | $1.12 |
| 2024 Q1 | UNCHANGED | 1,500 | — | 0% | 0.00% | $3K | $1.82 |
| 2023 Q4 | ADDED | 1,500 | +1,496 | +37400.0% | 0.00% | $1K | $0.79 |
| 2022 Q4 | INITIATED | 4 | — | — | 0.00% | $5 | — |
As of 2025 Q4 — sorted by position size